Aeterna Zentaris Settles Dispute with David Dodd and Philip Theodore
December 21 2018 - 5:04PM
Aeterna Zentaris Inc., (NASDAQ:AEZS) (TSX: AEZS)
has settled its previously disclosed litigation in South Carolina
and Canada with former officers of the Company, David Dodd and
Philip Theodore. As part of that settlement, the Company has agreed
to make a settlement payment to Mr. Dodd in the amount of $775,000.
About Aeterna Zentaris Inc.
Aeterna Zentaris Inc. is a specialty
biopharmaceutical company focused on developing and
commercializing, principally through out-licensing arrangements,
Macrilen™ (macimorelin), an oral ghrelin receptor agonist, to be
administered in the diagnosis of patients with adult growth hormone
deficiency. Aeterna Zentaris is a party to a license and
assignment agreement with a subsidiary of Novo Nordisk A/S to carry
out development, manufacturing, registration and commercialization
of Macrilen™ (macimorelin) in the United States and Canada. For
more information, visit www.zentaris.com.
Contact:
Leslie AuldChief Financial OfficerAeterna
Zentaris Inc.IR@aezsinc.com843-900-3201
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Apr 2023 to Apr 2024